Status:
COMPLETED
Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
Lead Sponsor:
Heron Therapeutics
Conditions:
Postoperative Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration int...
Eligibility Criteria
Inclusion
- Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
- Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
Exclusion
- Had any prior inguinal hernia repair.
- Has a planned concurrent surgical procedure.
- Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
- Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
- Has taken NSAIDs within 10 days prior to the scheduled surgery.
- Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
- Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.
- Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
- Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
- Has undergone 3 or more surgeries within 12 months.
- Has a body mass index (BMI) \>39 kg/m2.
Key Trial Info
Start Date :
July 31 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 16 2018
Estimated Enrollment :
418 Patients enrolled
Trial Details
Trial ID
NCT03237481
Start Date
July 31 2017
End Date
January 16 2018
Last Update
March 7 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Eliza Coffee Memorial Hospital
Florence, Alabama, United States, 35630
2
Shoals Medical Trials, Inc.
Sheffield, Alabama, United States, 35660
3
Arizona Research Center
Phoenix, Arizona, United States, 85053
4
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801